Literature DB >> 10938452

Multihormonal responses to clonidine in patients with affective and psychotic symptoms.

M Mokrani1, F Duval, T S Diep, P E Bailey, J P Macher.   

Abstract

The neuroendocrine responses to the alpha(2)-adrenoreceptor agonist clonidine (CLO) (0.35 mg if body weight <65 kg or 0.375 mg if body weight> or =65 kg, PO) were studied in a large group of subjects: 134 drug-free inpatients--with either DSM-IV schizophrenia (SCZ, n=31), schizoaffective disorder (SAD, n=16), or major depressive episode (MDE, n=87) - and 22 hospitalized controls (HCs). Comparison with a previous placebo test performed in a subgroup of 92 subjects (46 MDEs, 20 SCZs, 8 SADs, and 18 HCs) showed that CLO induced a significant increase of growth hormone, prolactin (PRL) and thyrotropin (TSH) levels but no significant change in adrenocorticotropin and cortisol release. According to diagnostic categories, we found significantly lower GH stimulation in MDEs and in SADs compared to HCs or to SCZs. In addition, we found significantly lower CLO induced PRL and TSH stimulations in paranoid SCZ patients compared to controls and disorganized SCZ patients. Taken together, these results suggest a hyposensitivity of noradrenergic alpha(2)-receptors in patients with affective symptoms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10938452     DOI: 10.1016/s0306-4530(00)00024-x

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  8 in total

1.  Persistent alterations in biological profiles in women with abuse histories: influence of premenstrual dysphoric disorder.

Authors:  Susan S Girdler; Jane Leserman; Robertas Bunevicius; Rebecca Klatzkin; Cort A Pedersen; Kathleen C Light
Journal:  Health Psychol       Date:  2007-03       Impact factor: 4.267

Review 2.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

3.  Platelet imidazoline receptors as state marker of depressive symptomatology.

Authors:  John Piletz; Robert Baker; Angelos Halaris
Journal:  J Psychiatr Res       Date:  2006-12-12       Impact factor: 4.791

4.  Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders.

Authors:  Fabrice Duval; Marie-Claude Mokrani; Alexis Erb; Vlad Danila; Felix Gonzalez Lopera; Ludovic Jeanjean
Journal:  Front Psychiatry       Date:  2020-09-18       Impact factor: 4.157

Review 5.  The roots of depression in adolescent girls: is menarche the key?

Authors:  Leslie Born; Alison Shea; Meir Steiner
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

Review 6.  Association of growth hormone deficiency (GHD) with anxiety and depression: experimental data and evidence from GHD children and adolescents.

Authors:  Fotini-Heleni Karachaliou; Kyriaki Karavanaki; Aristofania Simatou; Eleni Tsintzou; Nikitas S Skarakis; Christina Kanaka-Gatenbein
Journal:  Hormones (Athens)       Date:  2021-07-01       Impact factor: 2.885

7.  Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature.

Authors:  Daniel J Abrams; Donald C Rojas; David B Arciniegas
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

Review 8.  Prolactin and psychopathology in schizophrenia: a literature review and reappraisal.

Authors:  Ravi Philip Rajkumar
Journal:  Schizophr Res Treatment       Date:  2014-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.